Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials

References

• Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 [cited 2021 Jun 30];20:533–534. Available from: https://coronavirus.jhu.edu/map.html
   PubMed Web of Science ®Google Scholar
• Tillett R, Sevinsky J, Hartley P, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020;21(1):52–58.
   PubMed Web of Science ®Google Scholar
• Jácome R, Campillo-Balderas JA, Ponce de León S, et al. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. Sci Rep. 2020;10(1):9294.
   PubMed Web of Science ®Google Scholar
• Beck BR, Shin B, Choi Y, et al. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020;18:784–790.
   PubMed Web of Science ®Google Scholar
• Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, et al. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. J Antimicrob Chemother. 2021;76(7):1874–1885.
   PubMed Web of Science ®Google Scholar
• Mesci P, Macia A, Saleh A, et al. Sofosbuvir protects human brain organoids against SARS-CoV-2. Preprint. bioRxiv. 2020;2020.05.30.125856.
   Google Scholar
• Chen YW, Yiu CB, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. 2020;9:129.
   PubMedGoogle Scholar
• Pirzada RH, Haseeb M, Batool M, et al. Remdesivir and ledipasvir among the FDA-approved antiviral drugs have potential to inhibit SARS-CoV-2 replication. Cells. 2021;10(5):1052.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
   PubMed Web of Science ®Google Scholar
• Sadeghi A, Ali Asgari A, Norouzi A, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 2020;75(11):3379–3385.
   PubMed Web of Science ®Google Scholar
• Mobarak S, Salasi M, and Hormati A, et al. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalised COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). Preprint. SSRN. 2021;ssrn.3792895.
   Google Scholar
• Yakoot M, Eysa B, Gouda E, et al. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of COVID-19: a randomized, controlled study. Preprint. SSRN. 2021;ssrn.3705289.
   Google Scholar
• Yadollahzadeh M, Eskandari M, Roham M, et al. Evaluation of sovodak (sofosbuvir/daclatasvir) treatment outcome in COVID-19 patient’s compared with kaletra (lopinavir/ritonavir): a randomized clinical trial. Preprint. Res Square. 2021;rs.3.rs-257762/v1.
   Google Scholar
• Abbaspour Kasgari H, Moradi S, Shabani AM, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2020;75(11):3373–3378.
   PubMed Web of Science ®Google Scholar
• El-Bendary M, Abd-Elsalam S, Elbaz T, et al. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study [published online ahead of print, 2021 Jul 6]. Expert Rev Anti Infect Ther. 2021. DOI:https://doi.org/10.1080/14787210.2021.1950532.
   Google Scholar
• Elgohary MA, Hasan EM, Ibrahim AA, et al.Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: randomized controlled trial. Preprint. medRxiv.2021:2021.05.19.21257429.
   Google Scholar
• Nourian A, Khalili H, Ahmadinejad Z, et al. Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Acta Biomed. 2020;91(4):e2020102.
   PubMedGoogle Scholar
• Sayad B, Khodarahmi R, and Najafi F, et al. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2021 76 (8) ;2158–2167.
   PubMed Web of Science ®Google Scholar
• Alavi-moghaddam M, Haghighi M, and Sabaghian T, et al.Safety and efficacy of sofosbuvir in hospitalized adult patients with SARS-CoV-2: a preliminary report. SSRN. Preprint.2021:ssrn.3790463.
   Google Scholar
• Zein AFMZ, Sulistiyana CS, Raffaello WM, et al. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment [published online ahead of print, 2021 Jun 8]. Postgrad Med J. 2021;postgradmedj-2021-140287.
   Web of Science ®Google Scholar
• Abbass , S, Kamal, E, and Salama, MEfficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial J Med Virol 2021;93(12):6750-6759
   PubMed Web of Science ®Google Scholar
• Chan HT, Chao CM, Lai CC. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: a meta-analysis. J Infect. 2021;82(4):e34–e35.
   PubMed Web of Science ®Google Scholar
• Simmons B, Wentzel H, Mobarak S, et al. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis [published correction appears in J Antimicrob Chemother. 2021 May 12;76(6):1653]. J Antimicrob Chemother. 2021;76(2):286–291.
   PubMed Web of Science ®Google Scholar
• Rodriguez L, Brodin P. Unraveling the immune response in severe COVID-19. J Clin Immunol. 2020;40(7):958–959.
   PubMed Web of Science ®Google Scholar
• Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384(3):229–237.
   PubMed Web of Science ®Google Scholar
• Harvoni (ledipasvir/sofosbuvir) prescribing information. Foster City (CA): Gilead Sciences, Inc.; 2014 Oct.
   Google Scholar
• Daklinza (daclatasvir) prescribing information. Princeton (NJ): Bristol-Myers Squibb Company; 2016.
   Google Scholar
• Sayad B, Sobhani M, Khodarahmi R. Sofosbuvir as repurposed antiviral drug against COVID-19: why were we convinced to evaluate the drug in a registered/approved clinical trial? Arch Med Res. 2020;51(6):577–581.
   PubMed Web of Science ®Google Scholar
• McCracken NW, Blain PG, Williams FM. Nature and role of xenobiotic metabolizing esterases in rat liver, lung, skin and blood. Biochem Pharmacol. 1993;45(1):31–36.
   PubMed Web of Science ®Google Scholar
• Meier C. Nucleoside diphosphate and triphosphate prodrugs - an unsolvable task? Antivir Chem Chemother. 2017;25(3):69–82.
   PubMedGoogle Scholar